Pre-clinical Orthotopic Murine Model of Human Prostate Cancer.
To study the multifaceted biology of prostate cancer, pre-clinical in vivo models offer a range of options to uncover critical biological information about this disease. The human orthotopic prostate cancer xenograft mouse model provides a useful alternative approach for understanding the specific interactions between genetically and molecularly altered tumor cells, their organ microenvironment, and for evaluation of efficacy of therapeutic regimens. This is a well characterized model designed to study the molecular events of primary tumor development and it recapitulates the early events in the metastatic cascade prior to embolism and entry of tumor cells into the circulation. Thus it allows elucidation of molecular mechanisms underlying the initial phase of metastatic disease. In addition, this model can annotate drug targets of clinical relevance and is a valuable tool to study prostate cancer progression. In this manuscript we describe a detailed procedure to establish a human orthotopic prostate cancer xenograft mouse model.
Department of Urology, VA Medical Center and UCSF.
Varahram
V
Shahryari
Department of Urology, VA Medical Center and UCSF.
Hannah
H
Nip
Department of Urology, VA Medical Center and UCSF.
Sharanjot
S
Saini
California Pacific Medical Center Research Institute.
Altaf A
AA
Dar
Department of Urology, VA Medical Center and UCSF.
Soichiro
S
Yamamura
Department of Urology, VA Medical Center and UCSF.
Yozo
Y
Mitsui
Department of Urology, VA Medical Center and UCSF.
Melissa
M
Colden
Department of Urology, VA Medical Center and UCSF.
Nathan
N
Bucay
Department of Urology, VA Medical Center and UCSF.
Laura Z
LZ
Tabatabai
Department of Urology, VA Medical Center and UCSF.
Kirsten
K
Greene
Department of Urology, VA Medical Center and UCSF.
Guoren
G
Deng
Department of Urology, VA Medical Center and UCSF.
Yuichiro
Y
Tanaka
Department of Urology, VA Medical Center and UCSF.
Rajvir
R
Dahiya
Department of Urology, VA Medical Center and UCSF; Shahana.Majid@ucsf.edu.
Shahana
S
Majid
J Clin Invest. 2007 Oct;117(10):2962-73
17885682
Clin Cancer Res. 2003 Mar;9(3):1200-10
12631626
Prostate. 1999 May 15;39(3):182-6
10334107
Curr Protoc Pharmacol. 2010 Dec;Chapter 14:Unit 14.15
21483646
Cancer Res. 1999 Feb 15;59(4):781-6
10029062
Oncogene. 2010 Apr 1;29(13):1883-96
20101233
Clin Cancer Res. 2003 Nov 1;9(14):5161-70
14613995
Clin Exp Metastasis. 2003;20(2):135-41
12705634
Prostate. 1997 May 15;31(3):168-74
9167768
J Vis Exp. 2013 Sep 18;(79):e50873
24084571
Prostate. 1998 Feb 15;34(3):169-74
9492844
Clin Cancer Res. 1996 Sep;2(9):1627-36
9816342
Bone. 2011 Jan;48(1):141-51
20685406
J Natl Cancer Inst. 1992 Jun 17;84(12):951-7
1378502
Tumori. 2004 Nov-Dec;90(6):535-46
15762353
Invest New Drugs. 1999;17(4):343-59
10759402
CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29
25559415
J Natl Cancer Inst. 2006 Jun 7;98(11):783-93
16757703
J Clin Pathol. 2005 Jul;58(7):673-84
15976331
Cancer Res. 2008 May 1;68(9):3323-33
18451159